From Yahoo Finance: 2025-06-28 04:15:00

AbbVie Inc. is an undervalued S&P 500 stock to buy according to hedge funds. The global market for AbbVie’s Elahere, a treatment for ovarian cancer, is projected to grow from $502.56 million in 2024 to $6.07 billion by 2034, with a CAGR of 28.68%. AbbVie, through its acquisition of ImmunoGen, currently holds a 100% market share in the Elahere market. The largest segment for Elahere in 2024 was ovarian neoplasms, which accounted for $429.38 million. North America was the largest regional market for Elahere, representing $487.92 million. AbbVie is a research-based biopharmaceutical company specializing in medicines and therapies.



Read more at Yahoo Finance: AbbVie’s Elahere Market Expected to Skyrocket to $6B by 2034 in Ovarian Cancer Treatment